ClinicalTrials.gov record NCT02257866

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

Record copied from ClinicalTrials.gov: Oct 10, 2026AI summaries generated: Aug 22, 2026

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

StatusRecruitingThe study is currently enrolling participants. Only the study team can say whether a particular person can join.
Study typeObservationalA study in which researchers do not assign participants to a treatment or other intervention. They observe or measure what happens, which may include study visits, tests, questionnaires or a review of medical records.
Healthy volunteersAcceptedPeople who do not have the condition being studied who are allowed to take part. Some studies include both people with the condition and healthy volunteers; others may enrol only healthy volunteers.
Age3 years old and older
SexAll
LocationUnited States
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

This observational study follows people with different forms of idiopathic systemic vasculitis, some of their relatives, and healthy volunteers. Participants receive medical evaluations, give blood (and sometimes urine or nasal) samples, may have imaging scans, and may complete questionnaires. Visits can be a single 1–2 day (sometimes up to 4 day) evaluation, with some participants returning every 3–6 months for follow-up, potentially indefinitely.

What it is studying. The study is trying to learn signs, symptoms, imaging findings, genetic markers, and blood or tissue tests that help identify people with vasculitis and predict what happens to them over time. It also studies disease mechanisms (pathogenesis) — for example the role of neutrophils and selected biomarkers such as SERPINA1 — and searches for new candidate biomarkers in blood and local tissue sites (including the nasal lining). For a small number of participants and family members, whole genome or exome sequencing may be done.

What the researchers hope to learn. To define the natural history of idiopathic systemic vasculitis across age groups; to identify clinical, imaging, immunological, and genetic biomarkers linked to disease pathogenesis and outcomes; to develop disease activity measures that combine clinical, laboratory, genomic, and imaging markers; and to identify patients who might participate in future treatment studies.

What this study is about

The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.

Background:

  • Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse. Researchers want to study people's genes and follow people over time to see how the disease affects them.

Objective:

  • To learn the signs, symptoms, imaging tests, genetic markers, and blood tests that can help identify people with vasculitis and predict what will happen to them over time.

Eligibility:

  • People age 3 and older who have or are thought to have vasculitis, or are related to someone with it.
  • Healthy volunteers.

Design:

  • Participants will be evaluated by a doctor who has expertise caring for patients with vasculitis.
  • Participants will give a blood sample. Some will give a urine sample.
  • Some participants may have brushings or biopsies taken from the inside lining of the nose.
  • Images of participants' blood vessels may be taken using scans. For some scans, participants will lie on a table that moves in and out of a cylinder that takes pictures. For some scans, a contrast agent may be injected into an arm vein. Other scans may use a radioactive form of sugar. Healthy minors will not have scans.
  • Some participants will answer questionnaires. - Some participants will have their tests done at NIH. Others will have their doctor take the blood, saliva, or cheek swab samples and send them to NIH.
  • Some participants will have one visit lasting 1-2 (but sometimes up to 4) days. Some participants may have follow-up visits every 3 - 6 months, indefinitely.

Eligibility

The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.

Inclusion criteria

  • INCLUSION CRITERIA SUBJECTS WITH VASCULITIS:
  • Subjects with known or suspected diagnosis of idiopathic systemic vasculitis will be evaluated either at the outpatient or inpatient unit of the Clinical Center as indicated.
  • Subjects who fulfill modified versions of the 1990 American College of Rheumatology (ACR) Classification Criteria for GPA and PAN
  • Subjects who fulfill the 1990 ACR Classification Criteria for EGPA, GCA, and TAK
  • Subjects who fulfill the 2012 Chapel Hill Nomenclature definition for MPA
  • Subjects with other suspected systemic or single-organ vasculitides

Exclusion criteria

  • FOR SUBJECTS WITH VASCULITIS:
  • Subjects < 3 years of age
  • Active malignancy, infection, or any medical condition that in the opinion of the investigator would warrant exclusion
  • Inability to provide consent, or in the case of minors, assent
  • Subjects with bleeding diathesis or on anticoagulant medications (e.g. coumadin, heparin, clopidogrel but not including aspirin or NSAIDs) are excluded from participation in nasal brushing or biopsy studies
  • Reason for early termination
  • Withdrawal of consent
  • INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:
  • Healthy volunteers will be recruited to serve as controls for studies on peripheral blood samples.
  • Volunteers able to provide consent, or in the case of minors, assent
  • EXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:
  • Volunteers < 3 years of age risk
  • Diagnosis of vasculitis or other autoimmune/autoinflammatory disease, including systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis, mixed connective tissue disease or any overlap autoimmune syndrome
  • Active malignancy, infection, or any medical condition that in the opinion of the investigator would warrant exclusion
  • Pregnant (by history of last menstrual period) or breast-feeding subjects
  • Subjects with bleeding diathesis or taking anticoagulant medications (e.g. coumadin, heparin, clopidogrel but not including aspirin or NSAIDs) are excluded from participating in nasal brushing studies

Study description and what participation involves

The study's detailed description, as published on ClinicalTrials.gov.

Show the detailed description from the registry

The purpose of this protocol is to study the natural history of idiopathic systemic vasculitis in children and adults. The idiopathic vasculitides are a group of rare, systemic diseases involving inflammation of arteries and other tissue with resulting organ- and life-threatening disease courses. The different forms of idiopathic vasculitis are typically classified based upon the predominant size of the arteries affected in each condition, including small vessel vasculitis [granulomatosis with polyangiitis (GPA, Wegener s), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss)]; medium vessel vasculitis [polyarteritis nodosa (PAN)]; and large vessel vasculitis [giant cell arteritis (GCA), Takayasu s arteritis (TAK), idiopathic aortitis (IA)]. Although patients with each type of vasculitis manifest disease-specific aspects of illness, there are substantial disease and treatment burdens common to patients with vasculitis. For each type of idiopathic vasculitis, the disease course is often chronic, relapse is common and unpredictable, organ and tissue damage can accrue over time, new symptoms can occur late into the disease course, and treatment is often associated with toxicity and serious side effects. The goals of this natural history protocol are to establish a cohort of pediatric and adult patients with vasculitis to prospectively evaluate the signs and symptoms, imaging findings, and blood and tissue biomarkers associated with pathogenesis and disease outcomes. In the small vessel vasculitides, where considerable progress has been made towards identifying pathologic mechanisms of disease, we will focus on elucidating the pathogenic role of neutrophils, selected biomarkers such as SERPINA1, and novel candidate biomarkers in circulating blood and at local tissue sites including the nasal mucosa. In the medium and large vessel vasculitides, we will identify novel candidate biomarkers for disease pathogenesis and outcomes and develop disease activity indices that incorporate existing and novel clinical, laboratory, genomic, and imaging biomarkers. For all types of vasculitis, a goal of the protocol is to identify patients for possible entry into future treatment studies. Patients enrolled in this protocol will undergo a history, physical examination, and laboratory evaluation. Since vasculitis is multi-system disease with variable patterns of organ involvement, patients may undergo further comprehensive evaluation of a particular affected organ system when clinically indicated. Peripheral blood samples will be collected from affected patients, unrelated healthy volunteers matched for age, sex, and ethnicity whenever possible, and in some cases unaffected family members to help identify and study the genes involved in vasculitis and their functions. We may ask some patients to undergo nasal biopsy and additional imaging studies for research purposes. For a small number of patients and family members, we may ask permission to perform whole genome or exome sequencing. Successful completion of these studies will improve our understanding of disease pathogenesis.

AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴

AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.

Participants meet with a vasculitis specialist for a medical history and physical and may give blood samples; some will also provide urine, saliva, or cheek‑swab samples. Some people may have nasal brushings or a nasal biopsy (sampling from the inside lining of the nose). Participants may undergo imaging of blood vessels — scans that can involve lying on a table that moves into a cylinder, an injected contrast agent, or a scan using a radioactive form of sugar; the record notes healthy minors will not have scans. Visits range from a single 1–2 day visit (sometimes up to 4 days) to follow‑up visits every 3–6 months indefinitely; a small number of participants or family members may be asked to allow whole‑genome or exome sequencing, and some participants will complete questionnaires.

How the study is structured. This is a prospective observational cohort study. Participants are seen by doctors experienced in vasculitis and may give blood and sometimes urine samples; some may provide nasal brushings or biopsies. Imaging scans of blood vessels may be taken for some participants; certain scans may use an injected contrast agent or a radioactive sugar, and healthy minors will not have scans. Some tests and samples are collected at NIH while others can be taken by a participant's local doctor and sent to NIH. Follow-up visits may occur every 3–6 months and can continue long term.

Questions you could ask

These questions are suggestions for a conversation with the study team or your own clinician, not advice.

  • This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
  • The listed sites are in United States. Is any of them reachable for me, and does the study help with travel?
  • Which of the eligibility criteria would need to be checked with tests before I could join?

More on relapsing polychondritis

Important dates

Study start
Sep 29, 2014
Primary completion
Jan 1, 2050 (estimated)
Study completion
Jan 1, 2050 (estimated)
Target enrollment
4000 participants (estimated)
Last updated on registry
Oct 8, 2026
Data verified
Oct 10, 2026

Sponsor and research team

The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.

Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Central study contact

If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.

Participating sites (1)

  • National Institutes of Health Clinical CenterRecruiting

    Bethesda, Maryland, 20892 · United States

Terms used on this page · explanations by MedicalUpdates.ai

relapse
A condition that improved with treatment and has since returned or worsened.
follow-up
The period after treatment or enrolment during which participants are observed or contacted, for example to record side effects or outcomes.
INCLUSION CRITERIA
The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
assent
A child's or dependent adult's agreement to take part, given alongside the formal consent of a parent or legal representative.
biopsy
Removal of a small piece of tissue so it can be examined under a microscope. 'Biopsy-proven' or 'histologically confirmed' means the diagnosis was confirmed by examining tissue under a microscope.
EXCLUSION CRITERIA
The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
natural history
A study that follows how a condition changes over time without assigning an experimental treatment. It may involve study visits and tests, and is often used to plan future trials.
cohort
A group of people who share a characteristic, such as a diagnosis, and are studied together. 'Prospective' means they are followed forward from enrolment; 'retrospective' means existing records are reviewed.
biomarkers
Something measurable in the body, such as a blood test result or an imaging finding, that indicates how a condition or treatment is behaving.

The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.

← Back to clinical trials